Aurobindo Pharma Ltd. (NSE: AUROPHARMA) and Cipla Limited (NSE: CIPLA) are both listed in the Medicinal Chemicals and Botanical Products industry. Aurobindo Pharma has a market capitalisation of ₹96,882 Cr and Cipla ₹1,12,054 Cr, as of 9 Nov 2026. Their P/E ratios are 27.9 and 28.9 respectively. Return on equity is 9.93% for Aurobindo Pharma and 11.74% for Cipla. Over one year, Aurobindo Pharma's share price is up 62.9% and Cipla's is down 7.1%.
| Metric | Aurobindo Pharma | Cipla |
|---|---|---|
| NSE Symbol | AUROPHARMA | CIPLA |
| BSE Code | 524804 | 500087 |
| Share Price | ₹1,855.30 | ₹1,403.80 |
| Market Cap | ₹96,882 Cr | ₹1,12,054 Cr |
| P/E Ratio | 27.9 | 28.9 |
| Return on Equity | 9.93% | 11.74% |
| Return on Assets | 5.95% | 7.58% |
| Dividend Yield | 0.00% | 0.94% |
| Beta (1Y) | 0.14 | 0.01 |
| 1-Year Price Change | +62.9% | -7.1% |
| 3-Month Price Change | +12.6% | -4.4% |
| 52-Week Range | ₹1,106.00 – ₹1,856.10 | ₹1,165.70 – ₹1,539.70 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹10,263 Cr | ₹7,404 Cr |
| Quarterly Net Profit | ₹1,124 Cr | ₹852 Cr |
| Net Margin | 11.0% | 11.5% |
| EPS (Basic, Quarter) | ₹19.57 | ₹10.86 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HI…
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respirator…
Cipla has a market capitalisation of ₹1,12,054 Cr, against ₹96,882 Cr for Aurobindo Pharma as of 9 Nov 2026, about 1.2 times the size by market cap.
Aurobindo Pharma has a P/E of 27.9 and Cipla a P/E of 28.9 as of 9 Nov 2026.
Aurobindo Pharma has a return on equity of 9.93% and Cipla 11.74%.
Aurobindo Pharma's share price is up 62.9% over one year and Cipla's is down 7.1%.
Aurobindo Pharma reported revenue of ₹10,263 Cr and net profit of ₹1,124 Cr for Q2 FY27. Cipla reported revenue of ₹7,404 Cr and net profit of ₹852 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.